Objective: The GORE EXCLUDER Iliac Branch Endoprosthesis (IBE; W. L. Gore and Associates, Flagstaff, Ariz) is an iliac branch stent graft system designed to preserve internal iliac artery perfusion during endovascular repair of aortoiliac aneurysms (AIAs) and common iliac artery (CIA) aneurysms (CIAAs). We report the 6-month primary end point results of the IBE 12-04 United States pivotal trial for endovascular treatment of AIAs and CIAAs using the IBE device.
Endovascular aneurysm repair (EVAR) is the predominant method for treatment of abdominal aortic aneurysms (AAAs) in contemporary practice, 1 and between 20% and 30% of patients undergoing EVAR are estimated to also have associated iliac artery aneurysms. 2, 3 Patients with aortoiliac aneurysms (AIAs) undergoing conventional EVAR have a higher incidence of late complications, including distal type I endoleaks and iliac limb occlusions, compared with patients without iliac aneurysms undergoing EVAR. 2 In addition, patients with
AIAs have a higher likelihood of needing secondary procedures after EVAR. 4 The presence of iliac aneurysms may also limit the applicability of traditional EVAR unless additional adjunctive treatment strategies are used, highlighting the clinical need for new endovascular devices designed for the treatment of AIAs. The "coil-and-cover" technique with embolization of the internal iliac artery and extension of the stent graft limb into the external iliac artery has routinely been used as an adjunct during EVAR when treating patients with common iliac artery (CIA) aneurysms (CIAAs) or AIAs involving the iliac bifurcation. Although enabling successful exclusion of a CIAA during EVAR, internal iliac artery sacrifice is associated with pelvic ischemic complications such as buttock claudication, erectile dysfunction, colon ischemia, pelvic necrosis, lower extremity neurologic deficits, and paraplegia. 5 Intentional occlusion of an internal iliac artery during EVAR results in new-onset buttock claudication and erectile dysfunction in w28% and 17% of patients, respectively, and bilateral internal iliac occlusion is associated with increased risk of pelvic ischemic complications. 6 Buttock claudication symptoms may improve over time but persist in more than half of affected patients 1 year after EVAR and can have a significant negative effect on patient quality of life. 7, 8 Fortunately, the more serious and potentially life-threatening complications of colon ischemia, pelvic necrosis, and spinal cord injury are less common, affecting w1% of patients. [9] [10] [11] In an effort to avoid pelvic ischemic complications, multiple techniques have been described for preservation of internal iliac artery perfusion during EVAR in patients with CIAAs and AIAs. Hybrid procedures to preserve internal iliac artery perfusion include creation of surgical externaleto-internal iliac bypass, followed by EVAR, 12 and insertion of an external iliac-to-internal iliac stent graft, femoral-femoral bypass, and EVAR with an aortomonoiliac stent graft. 13 These techniques are effective in preventing ischemic complications, but expose patients to morbidity from open surgical procedures. A number of purely endovascular solutions have also been proposed, including surgeon-modified branched iliac limbs, 14 "sandwich" techniques with parallel stent grafts, 15 trifurcated stent grafts, 16 and use of "bell-bottom" limbs. 17 Dedicated iliac branch devices have subsequently been developed specifically for preservation of internal iliac artery perfusion during EVAR in patients with AIA or CIAA. These bifurcated stent grafts have a limbs that are extended into the internal and external iliac arteries to preserve pelvic and lower extremity blood flow. Several centers have reported use iliac branch devices during treatment of AIAs, with high rates of technical success and branch patency and low rates of reinterventions. [18] [19] [20] [21] [22] Notably, patients with patent iliac branch devices do not experience buttock claudication. 23 Most early reports detailing EVAR with iliac branch devices used the Zenith Iliac Branch device (Cook, Inc, Bloomington, Ind). Subsequently the GORE EXCLUDER Iliac Branch Endoprosthesis (IBE; W. L. Gore and Associates, Flagstaff, Ariz) was developed, and several centers have reported similar favorable results. [24] [25] [26] [27] Here we report the results from a prospective, multicenter, single-arm study designed to examine the safety and effectiveness of the Gore IBE for treatment of CIAA and AIA.
METHODS
Study design. The IBE 12-04 study was a prospective, multicenter, single-arm trial was designed to assess the safety and effectiveness of the IBE device in patients with CIAA or AIA. Sixty-five patients who met all the inclusion criteria and none of the exclusion criteria (Fig 1) were enrolled at 28 investigative sites in the United States (U.S.) from October 2013 to January 2015. Patients were considered enrolled once the IBE device was inserted. In patients with bilateral CIAAs, only one of the iliac arteries could be treated with the IBE device after staged embolization or surgical revascularization of the internal iliac artery on the opposite side. Patients with bilateral aneurysms were considered enrolled once the staged procedure for management of the opposite internal iliac artery procedure was initiated.
All patients gave written informed consent, and the study was conducted in accordance with U.S. Federal regulations and with Institutional Review Board approval from each investigative site. An independent Data Safety Monitoring Board was established and consisted of an interdisciplinary team of four appropriately qualified medical professionals and one biostatistician who were not directly involved in the conduct of the study. A Clinical Events Committee (CEC), consisting of a panel of five members, adjudicated safety and effectiveness end point events and inclusion/exclusion criteria deviations to assess their effect on the potential risk for experiencing a safety or effectiveness end point event. An imaging core laboratory, AortaCore located at the University of Wisconsin-Madison, was used to provide an independent review of computed tomography (CT) scans collected for the study. A Bilateral Recommendation Committee, consisting of a panel of three experienced investigators, reviewed imaging for individuals with bilateral CIAs who were eligible for enrollment into the IBE trial, if time permitted. Member(s) of the committee made nonbinding treatment recommendations, including which side to treat, to the treating investigator in instances when the left and right iliac arteries both met anatomic requirements for the IBE device. Members were chosen based on their experience or knowledge of endovascular repair of CIAAs, or both, and were study investigators in the study.
ARTICLE HIGHLIGHTS
Device description. The IBE device (Fig 2) consists of two modular components: the Iliac Branch Component (IBC) and the Internal Iliac Component (IIC). The IBE device is designed to be used in conjunction with the GORE EXCLUDER AAA Endoprosthesis. The IBC is an iliac branch device intended to be placed within the CIAA and has two limbs, a longer external iliac limb and a shorter internal iliac limb (gate). The IIC is positioned within the gate of the IBC to extend the internal iliac limb into the main internal iliac artery. The IBC is delivered through a 16F sheath over a stiff guidewire and a femoral-femoral through wire that passes through the precannulated internal lilac gate. A 12F sheath is inserted from the contralateral femoral artery and is advanced over the through wire into the internal iliac gate. The IIC is introduced through the 12F sheath into the internal iliac artery. After insertion of the IBE device, the GORE EXCLUDER AAA Endoprosthesis is inserted. A 23-or 27-mm-diameter iliac limb is used to connect the aortic trunk component of the GORE EXCLUDER AAA Endoprosthesis with the IBC. Further detailed information is provided in the IBE device instructions for use (IFU; http://www.goremedical.com/ assets/MD141541/MD1415411.pdf).
Study end points. The primary safety end point of this study was a composite of the following major adverse events based on the definitions provided by Chaikof et al 28 : death, stroke, myocardial infarction, bowel ischemia, paraplegia, respiratory failure, renal failure, and conversion to open surgical repair #30 days of the initial procedure. The primary effectiveness end point of this study is a composite of the following events through the 6-month follow-up visit: reintervention on the IBC or the IIC due to type Ib or type III endoleak as determined by the CEC, complete loss of blood flow in the leg of the IBC or the IIC due to thrombus or device failure as assessed by an independent core laboratory, and reintervention on the IBC or IIC to re-establish patency due to >60% stenosis or occlusion as determined by the CEC.
The secondary effectiveness end point is defined as new-onset buttock claudication arising from the side of the body treated with the IBC and IIC through the 6 month follow-up visit. Candidate secondary effectiveness end point events were adjudicated by the CEC.
RESULTS
Of 173 patients who were screened, 64 patients met all inclusion and exclusion criteria and were enrolled into the study. One patient was withdrawn from the study before the procedure due to an insurance coverage denial, leaving 63 patients (98.4% male) who underwent the IBE device procedure (Fig 3) . The patients were a mean age of 69.6 6 8.4 years (range, 51-88 years), and 59 were white (92.2%).
The CIAA was unilateral in 39 patients (60.9%) and was bilateral in 25 (39.1%). AAAs >50 mm diameter (mean, 57.2 6 5.5 mm; range, 49.6-67.1 mm) were present in 25 patients (39.1%), and 39 patients (60.9%) had a maximum aortic diameter <50 mm (mean, 37.5 6 7.6 mm; range, 20.7-49.1 mm). CIAA anatomic characteristics on the IBE device treatment side are presented in Table I . The mean CIAA maximum diameter on the IBE side was 41.9 6 11.0 mm (range, 25.5-75.9 mm), and the mean CIAA minimum flow lumen diameter was 16.5 6 3.5 mm (range, 9.3-24.9 mm). Mean renal artery-to-CIA bifurcation length on the IBE device side was 197.9 6 24.7 mm (range, 158.6-281.1 mm). A minimum CIA length was not part of the study inclusion and exclusion criteria, and this was not determined by the core laboratory. The mean CIA length on the IBE device side was available only from site-reported data and was 71.2 6 23.1 mm (range, 25.0-135.0 mm).
Procedural details. The IBE device was implanted in 63 patients. Details of the IBE implantation procedure are presented in Table II . General anesthesia was used for 55 patients (87.3%), and local anesthesia was used for eight patients (12.7%). Access on the IBE device side was percutaneous in 31 patients (49.2%), surgical exposure in 31 (49.2%), and via iliac conduit in 1 (1.6%). Access on the non-IBE device side was percutaneous in 30 (47.6%), surgical exposure in 32 (50.8%), and via iliac conduit in 1 (1.6%). Mean procedure time was 151.8 6 47.6 minutes (range, 68-334 minutes). Mean blood loss was 247.6 6 181.9 mL (range, 0-1000 mL).
Overall technical success was 95.2% (60 of 63). Reasons for failure to achieve technical success were (1) use of a commercially available GORE EXCLUDER AAA Endoprosthesis Iliac Extender in the internal iliac artery
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Bilateral iliac aneurysm subject withdrew and re-enrolled as unilateral iliac aneurysm subject instead of an IIC; (2) presence of a small type Ib endoleak at completion of the IBE device procedure; and (3) a type III endoleak between the IBC and the bridging iliac limb noted at time of final angiography. Both endoleaks resolved and were not observed on the 1-month or the 6-month follow-up CT scans. Median hospital stay after endovascular treatment with the IBE device was 2.0 6 1.8 days (range, 1-11 days). An intensive care unit stay was required in 22.2% of patients and was a mean length of 1.4 6 0.8 days (range, 1-3 days). Hospital and 30-day survival was 100%. The mean time to return to normal daily activities was 32.5 6 41.0 days (range 1-205 days). No primary safety end point major adverse events (death, stroke, myocardial infarction, bowel ischemia, paraplegia, respiratory failure, renal failure, or conversion to open surgical repair) were observed in this study. Through 30 days, nine patients (14.3%) experienced other serious adverse events, the most common being urinary tract infection in three patients (4.8%). The other recorded serious adverse events occurred in one patient (1.6%) each and included hematoma, hypoxia, incision site infection, artery dissection, pulmonary embolism, tachycardia, and urinary retention.
Staged procedures. Twenty-three patients with bilateral CIAA underwent a staged procedure to occlude or revascularize the contralateral internal iliac artery before the IBE device procedure. Embolization of the internal iliac artery on the non-IBE device side was performed in 21 patients with coils in 17 (73.9%) or vascular plug(s) in four (17.4%). One patient underwent surgical internal iliac artery revascularization, and in one patient, angiography at the time of the staged procedural revealed that the internal iliac artery on the non-IBE device side was already occluded. Mean staged procedure time was 81.4 6 59.5 minutes (range, 30-256 minutes). Mean procedural blood loss was 70.7 6 178.1 mL (range, 0-750 mL). All patients survived the staged procedure, and in 95.7%, the procedure was completed successfully. The staged coil embolization procedure was unsuccessful in one patient because of arterial tortuosity, but was later completed in a second staged procedure.
Primary effectiveness end point. Sixty-one patients were eligible for primary effectiveness end point analysis by meeting the inclusion/exclusion criteria and having both IBE components implanted. Follow-up imaging data are summarized in Table III . Through 6 months of follow-up, three patients experienced loss of patency of the IIC of the IBE device. All three were complete IIC occlusions and were detected on the 1-month follow-up CT scan. No additional occlusions were detected at the 6-month follow-up. (Patients missing 6-month CT scans, but with CT scans showing patent IBE components at later assessments, were assumed to have patency at the 6-month end point.) All occlusions were asymptomatic and did not require interventions. There were no No type I or type III endoleaks were detected on the 1-month or 6-month follow-up CT scans. Type II endoleaks were observed in 57.9% (33 of 57) of patients with contrast CT scans and in 54.7% (29 of 53) of patients with contrast CT scans at 1 month and 6 months, respectively. Two patients underwent reinterventions. One reintervention was on postoperative day 26 for treatment of an external iliac artery dissection distal to the IBE device with placement of a bare-metal stent. The other reintervention was on postoperative day 252 for treatment of a type II endoleak with embolization. No wire fractures, device migrations, or device intercomponent separations were observed.
CT scan data were available from 57 patients to determine aneurysm diameter changes at the 6-month follow-up. Four patients (7.0%) had a $5-mm decrease in abdominal aortic diameter, 53 patients (93.0%) had no change in abdominal aortic diameter, and no patients experienced abdominal aortic growth. At 6 months, six patients (10.5%) had a $5mm decrease in CIAA diameter, 51 patients (89.5%) had no change in CIAA diameter, and no patients experienced CIAA growth in orthogonal view, although one patient (1.8%) had a $5-mm increase in CIAA diameter in the axial view. Through 6 months of follow-up, there was one nonaneurysmal-related death due to a myocardial infarction, and there were no aneurysm ruptures or aneurysm-related deaths.
Secondary effectiveness end point. All patients were free from new-onset buttock claudication on the side of the IBE device through 6 months of follow-up, including the three patients who experienced IIC occlusions. The incidence of buttock claudication in the 21 patients who underwent staged procedures to occlude the contralateral internal iliac artery was 28.6% (6 of 21).
DISCUSSION
Several retrospective studies have shown that iliac branch devices can effectively exclude CIAAs during EVAR, preventing complications otherwise associated with internal iliac artery sacrifice and providing high rates of patency and good freedom from reintervention. The current prospective, multicenter, pivotal study provides further evidence, demonstrating that that the GORE EXCLUDER IBE device can be implanted with high rates of technical success and is safe and effective. Short-term outcomes through 6 months showed >95% internal iliac artery branch primary patency, 100% freedom from type I and type III endoleaks and aneurysm rupture, and a low overall reintervention rate. However, we observed a high incidence of type II endoleaks, which were present in >50% of patients at 6 months. The increased number of type II endoleaks did not appear to have any significant adverse effect on clinical outcomes, such as aneurysm enlargement or reintervention rates, and may be related to improved imaging techniques, but it was slightly increased compared with historical clinical data for the EXCLUDER stent graft. Use of the IBE device also effectively prevented the development of ipsilateral buttock claudication and other pelvic ischemic complications otherwise associated with internal iliac artery sacrifice during EVAR.
These results parallel the reports outside the U.S. where early experience using Zenith iliac branch devices during EVAR was compiled in a systematic review by Karthikesalingam et al, 29 who reviewed results from nine different series including 196 patients. The combined results showed initial rates of technical success ranging from 85% to 100%. Clinical success, defined as prevention of buttock claudication and an intention-totreat basis, varied significantly, ranging from 63% to 88%. Internal iliac artery branch occlusions were reported in 24 of 196 patients (12.2%), and in 12 of the 24 patients (50%), occlusion resulted in onset of buttock claudication. Type I and type III endoleaks occurred in only one and two patients, respectively, and 12 patients (6.0%) underwent reinterventions. More recent and larger series have reported improved results with the Zenith device: Parlani et al 20 reported treatment of 100 patients with 120 iliac branch devices with a median follow-up of 21 months. Their 5-year estimated iliac branch patency was 91%, and freedom from reintervention was 81%. Austermann et al 30 reported similar results with up to 10 years of follow-up in 176 patients treated using 210 iliac branch devices. In their series, branch occlusion affected only 1% of devices, claudication occurred in 3% of patients, and 0.6% of patients experienced new-onset sexual dysfunction. Finally, the largest single-center U.S. experience with the Zenith device within a physician-sponsored investigational device exemption study was reported by Wong et al. 21 They implanted 138 iliac branch devices into 130 patients and reported 94% technical success and 81.8% branch patency at 5 years.
The GORE EXCLUDER IBE device has a dedicated internal iliac branch component, in contrast to the Zenith iliac branch device, which has been used with a variety of different covered stents for the limb extension into the internal iliac branch. Data with the more recently developed IBE device remain limited, but initial reports outside of the U.S. have been promising. [24] [25] [26] The largest series was recently reported by van Sterkenburg et al 27 and included a review of 51 IBE devices implanted into 46 patients at 13 institutions in The Netherlands. Technical success was 93.5%, and there were no deaths. At the 30-day follow-up, there was one IIC occlusion (2%) and no type I or type III endoleaks. Two patients (4.6%) reported new-onset buttock claudication ipsilateral to the IBE device, and one patient (2.3%) reported erectile dysfunction postoperatively. With follow-up up to 6 months, internal iliac branch patency was 94%, which is nearly identical to the IBE device patency we observed in our study. Loss of patency of the IIC in internal iliac artery occurred in three of 61 patients for an overall occlusion rate of 4.9% in our study. All of the occlusions were asymptomatic Patients with diameter change data (baseline, 1 month, and follow-up) . 57 .
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Abdominal aorta and were observed on the 30-day follow-up imaging studies. The early occurrence of these events suggests that they may have been related to technical or anatomic factors. Each case was analyzed for possible technical or anatomic factors that could have contributed to device thrombosis. Possible causes for failure that were identified included excessive oversizing of the IIC component (outside of the IFU guidelines) and landing the end of the IIC at a site of arterial tortuosity or at a site of significant atherosclerotic occlusive disease. These observations emphasize the importance of appropriate patient selection and adherence to manufacturer IFU guidelines for optimal outcomes. Although internal iliac artery sacrifice before or during EVAR is generally well tolerated, buttock claudication symptoms will develop in at least 20% of patients. 6 In our prospective study, we confirmed that the rate of buttock claudication after internal iliac artery occlusion is significant, occurring in 26% of patients who underwent staged procedures to occlude the internal iliac artery on the side opposite the IBE device. Symptoms may improve with time, but at least half of the patients are left with chronic symptoms that can affect quality of life. 7 Importantly, pelvic ischemic complications are effectively prevented when internal iliac artery patency is maintained by use of internal iliac branch devices. 23 Indeed, in the present study we found complete freedom from new-onset buttock claudication on the side of the IBE repair. Of course, risks of pelvic ischemic complications need to be balanced against added case complexity and device costs when treating CIAAs, but it seems reasonable to suggest that use of iliac branch devices should be favored over internal iliac artery sacrifice in most patients with appropriate anatomy. Less than half of the patients screened for the present study met inclusion and exclusion criteria and qualified for enrollment. The most common anatomic factors that deemed patients unsuitable for treatment with the IBE device were CIA lumen diameter <17 mm and inadequate internal iliac artery landing zones because of the presence of an internal iliac artery aneurysm or severe occlusive disease. Karthikesalingam et al 31 also found that >60% of patients have at least one anatomic limitation precluding use of an iliac branch device based on strict IFU criteria. A recent review in two U.S. centers found nearly two-thirds of patients were excluded from iliac branch device clinical trials for anatomic reasons, often due to lack of an internal iliac landing zone or inadequate luminal diameter of the CIA. 32 In their review, more patients met anatomic suitability for the IBE device (25.3%) than the Zenith device (18.2%). One limitation of their analysis is that a minimum CIA length requirement of >40 mm was incorrectly applied for the IBE device. However, there was no minimum CIA length requirement in our study. Therefore, it is possible that rates of morphologic suitability for the IBE device may be even higher than they reported. Applicability of iliac branch devices might be extended as operator experience increases and through use of adjunctive new techniques. For example, Austermann et al 30 described use of iliac branch devices to treat patients with aneurysmal internal iliac arteries by extending the internal iliac artery branch distally into the posterior division branch. In the largest U.S. single-center series, reported by Wong, et al, 21 70% of the patients they treated did not meet IFU criteria, most commonly because of an internal iliac artery aneurysm or stenosis. The internal iliac limb in 45% of their patients was extended distally, usually into the posterior division branch. Although adverse anatomic factors were associated with decreased technical success, long-term patency was not adversely affected.
Another common limitation in prior reports is a minimum CIA length requirement of 50 mm from the aortic bifurcation to the iliac bifurcation. In the current study, there was no minimum CIA length requirement. The length of the CIAs treated with the IBE device ranged from 25.0 mm to 135.0 mm, and in 27% of patients (17 of 63), the proximal end of the IBE device was placed above the aortic bifurcation. In each of these cases, the IIC was successfully delivered from a contralateral femoral artery approach without any negative effect observed on technical success or clinical outcomes. However, if the IIC component cannot be delivered from the femoral approach, an alternative covered stent theoretically could be delivered from brachial or axillary artery access. Although our study represents one of the first prospective, multicenter studies to examine the use of iliac branch devices, several limitations need to be acknowledged. There was no control arm or randomization to allow comparisons between EVAR with the IBE device and EVAR with internal iliac artery coil embolization. The 26% incidence of new-onset buttock claudication after contralateral internal iliac artery sacrifice in the patients who underwent staged procedures vs 0% on the IBE side strongly suggests that the IBE can prevent new-onset buttock claudication. However, in the absence of randomization, selection bias cannot be excluded.
In addition, because our follow-up data are limited to 6 months, the long-term durability of AIA or CIAA repair with the IBE device remains unknown. Additional data collection on durability and longer-term outcomes will be forthcoming because patients in the present study will be prospectively monitored for 5 years.
CONCLUSIONS
The GORE EXCLUDER IBE device is safe and effective for the treatment of AIAs and CIAAs. Internal iliac artery preservation using the IBE device is feasible, with high rates of technical success, safety, and device patency through 6 months of follow-up. Patients treated with the IBE device experience freedom from new-onset buttock claudication and other pelvic ischemic complications previously associated with internal iliac sacrifice during EVAR. Follow-up will continue for 5 years to establish the long-term durability of the IBE device. 
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